Overcoming Obesity: From Drug Discovery to Societal Impact
summary
Obesity is framed as a brain disease with roughly 70% genetic contribution and ~3 million deaths yearly, and drug development uses engineered hormone polyagonists targeting GLP‑1, GIP and glucagon. Mouse and human trials show 20–40% weight loss; Mounjaro (tirzepatide) delivers about 23% mean weight loss and normalizes glucose in ~50% of treated diabetes patients while reducing liver fat dramatically. New GIP‑glucagon dual agonist candidates report similar efficacy with far less nausea and GI toxicity.
AI-written summary · about
chapters (10)
- 0:00Obesity crisis overview
- 1:05Genetics of obesity
- 2:29Drug discovery in obesity
- 4:11Targeting brain hormones
- 5:55Dual and triple agonists
- 8:19Quintuple receptor agonist
- 9:44Drug side effects and limits
- 10:48GIP-glucagon dual agonists
- 11:28Health impacts beyond weight loss
- 12:53Obesity drugs' societal costs
related talks
38mBig data in personalised medicine
17mNews in Drug Development & AI
31mTowards Making Identification of Noncoding Causes of Human Disease Routine
30mMachine Learning: A New Approach to Drug Discovery
19mDeep Reinforcement Learning based Insulin Controller for Effective Type-1 Diabetic Care
30mLeveraging Molecular Data for Drug Discovery
14mIt's Time To Talk About Precision Health
20mTranslating a Trillion Pointo Diseases of Data into Therapies